Expanded Access of Dupilumab in Adults With Severe Immunoglobulin E (EgE)-Mediated Food Allergy Previously Treated With Linvoseltamab
- Sponsor
- Regeneron Pharmaceuticals
- Study ID
- NCT06631677
- Status
- Temporarily Not Available
Conditions
- Food Allergy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Dupilumab — DRUGAdministered per protocol
Study Details
This is an expanded access program of dupilumab. The objective of the program is to provide continued dupilumab to adult participants with severe IgE-mediated food allergy who were previously treated with a short course of linvoseltamab and background dupilumab in the parent study R5458-668-ALG-2219 (NCT06369467).
Key Dates
- Status verified
- May 2026
Related Studies
- Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic DisordersRecruiting · Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio
- Molecular Basis of Food AllergyEnrolling By Invitation · Children's Hospital of Philadelphia · Philadelphia, Pennsylvania
- Natural History and Genetics of Food Allergy and Related ConditionsRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- Prescreening Protocol to Enroll in Food Allergy Clinical Studies at a Single SiteRecruiting · Stanford University · Palo Alto, California